These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21880200)

  • 21. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 22. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.
    Kraemer M; Uekermann J; Wiltfang J; Kis B
    Clin Neuropharmacol; 2010 Jul; 33(4):204-6. PubMed ID: 20571380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attention-deficit/hyperactivity disorder: advances in diagnostic and therapeutic approaches.
    DelBello MP
    J Clin Psychiatry; 2008 Jan; 69(1):130. PubMed ID: 18312047
    [No Abstract]   [Full Text] [Related]  

  • 25. A review of studies of drug treatment efficacy for attention deficit disorder with hyperactivity in adolescents.
    Varley CK
    Psychopharmacol Bull; 1985; 21(2):216-21. PubMed ID: 2860692
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Quinn D; Bode T; Reiz JL; Donnelly GA; Darke AC
    J Clin Pharmacol; 2007 Jun; 47(6):760-6. PubMed ID: 17395894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life of methylphenidate treatment-responsive adolescents with attention-deficit/hyperactivity disorder.
    Yang PC; Lung FW; Chiou SS; Yen CF; Fuh JL
    Kaohsiung J Med Sci; 2012 May; 28(5):279-84. PubMed ID: 22531308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visual fields in children with attention-deficit/hyperactivity disorder before and after treatment with stimulants.
    Ghanizadeh A
    Acta Ophthalmol; 2010 Mar; 88(2):e56. PubMed ID: 19508459
    [No Abstract]   [Full Text] [Related]  

  • 30. Attention-deficit-hyperactivity disorder.
    Diller LH
    N Engl J Med; 1999 Jun; 340(22):1766; author reply 1767. PubMed ID: 10357639
    [No Abstract]   [Full Text] [Related]  

  • 31. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of discontinuation of methylphenidate at adolescence onset on adult attention deficit hyperactivity disorder].
    Papazian O; Alfonso I; García V
    Rev Neurol; 2002 Jul 1-15; 35(1):24-8. PubMed ID: 12389188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence and belief in attention deficit hyperactivity disorder. Reintroduction of methylphenidate in Italy needs careful monitoring.
    Bonati M; Impicciatore P; Pandolfini C
    BMJ; 2001 Mar; 322(7285):556. PubMed ID: 11263458
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of attention-deficit-hyperactivity disorder.
    Elia J; Ambrosini PJ; Rapoport JL
    N Engl J Med; 1999 Mar; 340(10):780-8. PubMed ID: 10072414
    [No Abstract]   [Full Text] [Related]  

  • 35. Attention deficit hyperactivity disorder: part III.
    Ryan-Krause P
    J Pediatr Health Care; 2011; 25(1):50-6. PubMed ID: 21147408
    [No Abstract]   [Full Text] [Related]  

  • 36. [ADD psychosis: treatment with antipsychotics and methylphenidate?].
    Blom JD; Kooij JJ
    Tijdschr Psychiatr; 2012; 54(1):89-93. PubMed ID: 22237615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The evaluation of the effects of pharmacological treatment of children with attention deficit hyperactivity disorder].
    Roselló B; Amado L; Presentación MJ
    Rev Neurol; 1999 Feb; 28 Suppl 2():S177-82. PubMed ID: 10778510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
    Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
    Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attention-deficit/hyperactivity disorder: a personal perspective.
    Ginsberg ML
    Adolesc Med State Art Rev; 2008 Aug; 19(2):339-51, xi-xii. PubMed ID: 18822837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel multidomain computerized cognitive assessment for attention-deficit hyperactivity disorder: evidence for widespread and circumscribed cognitive deficits.
    Leitner Y; Doniger GM; Barak R; Simon ES; Hausdorff JM
    J Child Neurol; 2007 Mar; 22(3):264-76. PubMed ID: 17621495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.